Apremilast in the Treatment of Moderate to Severe Acne
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Acne is a chronic inflammatory disease of the pilosebaceous unit that affects 80-90% of the
population, especially teenagers, although adult acne is a significant problem for 3-6 % of
adult men and 5-12% of adult women. Although acne is not a life-threatening disease, it
produces significant psychological disturbances and permanent skin scars.
A novel anti-inflammatory, not antibiotic drug may be an excellent alternative for the
treatment of moderate to severe acne. Apremilast has been shown to inhibit the production of
tumor necrosis factor (TNF)-alpha, IL-8 and neutrophil infiltration, all of which are
elevated in inflammatory acne.
Our intention is to study Apremilast in the treatment of moderate to severe acne.